0000358654
Donate

Reimbursement status:
Reimbursement with restrictions

Cancer: Lymphocytic leukaemia

Indication:

Obinutuzumab in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XC
L01XC Monoclonal antibodies
EMA approval status :
Approved
EMA approval date :
2014-07-23
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
Yes